Cure Rare Disease Announces Partnership with Columbus Children's Foundation
Companies Unite in an Effort to Drive the Development of Drugs for Rare Diseases Globally
Boston, Massachusetts--(Newsfile Corp. - August 19, 2020) - Cure Rare Disease (CRD), the emerging, Boston-based nonprofit on a mission to develop customized therapeutics for rare diseases, announced a strategic partnership with Columbus Children's Foundation (CCF), a nonprofit biotech known for its role in the advancement and acceleration of gene therapy programs bringing hope to children with ultra-rare genetic diseases. In addition to advancing its internal programs for ultra-rare diseases, CCF is partnering with contract development and manufacturing organizations (CDMOs) such as Viralgen Vector Core (VVC), a leading manufacturer of Adeno-associated virus (AAV) vectors for gene therapy, to provide, expertise, access to capacity and significantly discounted Adeno-associated viruses (AAV) for ultra-rare diseases and mutations for which there's limited therapeutic availability.
To view the full announcement, including downloadable images, bios, and more, click here.
- Cure Rare Disease is partnering with Columbus Children's Foundation to address the economic accessibility issues that nonprofit ultra-rare drug development programs face.
- Manufacturing is one of the most difficult steps and CCF is helping to close the rare disease divide.
- Working with CCF and their partners, like VVC, offers access to support in the AAV field, paired with a high-quality product that's being produced for the first custom treatment for Duchenne muscular dystrophy pending FDA approval.
Select image to view the full announcement, including downloadable images, bios, and more.
About Cure Rare Disease (CRD)
CRD is a Boston-based nonprofit biotechnology company founded by Rich Horgan, Blavatnik Life Science Entrepreneur-in-Residence at Harvard Business School who has witnessed three generations of his family affected by Duchenne muscular dystrophy, a fatal, neuromuscular disease. As anyone who is touched by a fatal, rare disease knows, time is of the essence. To overcome the obstacles inherent in the existing model of drug development, CRD has taken a new approach, forming an unprecedented collaboration with leading researchers and institutions nationwide in genetics, genomics, bioinformatics and biotechnology. Horgan and team are pioneering the development of a new platform for customized therapeutic treatments that can be applied to a range of rare, genetic diseases, and aim to inspire hope for a cure. Learn more at www.cureraredisease.org.
About Columbus Children's Foundation (CCF)
CCF's mission is to ensure equitable and affordable access to the most effective gene therapy solutions for children with ultra-rare genetic diseases. CCF uses a nonprofit model to partner and accelerate gene therapy treatments for programs with very small patient populations that are often overlooked because the economics don't add up for those using a traditional commercial development model. Through strategic partnerships with other foundations, industry, patient groups and philanthropy; CCF aims to bring the scientific and funding resources together on behalf of the many ultra-rare diseases to accelerate hope and transform the lives of those fighting these devastating diseases. Learn more a www.columbuschildren.org
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/62033